### Title:

Improving diagnosis of non-malarial fevers in Senegal: *Borrelia* and the contribution of tickborne bacteria

## Authors:

Zoë C. Levine<sup>1,2,3</sup>, Aita Sene<sup>4</sup>, Winnie Mkandawire<sup>1,5</sup>, Awa B. Deme<sup>4</sup>, Tolla Ndiaye<sup>4</sup>, Mouhamad Sy<sup>4</sup>, Amy Gaye<sup>4</sup>, Younouss Diedhiou<sup>4</sup>, Amadou M. Mbaye<sup>4</sup>, Ibrahima Ndiaye<sup>4</sup>, Jules Gomis<sup>4</sup>, Médoune Ndiop<sup>6</sup>, Doudou Sene<sup>6</sup>, Marietou Faye Paye<sup>1</sup>, Bronwyn MacInnis<sup>1,7</sup>, Stephen F. Schaffner<sup>1,7,8</sup>, Daniel J. Park<sup>1</sup>, Aida S. Badiane<sup>4</sup>, Andres Colubri<sup>1,5</sup>, Mouhamadou Ndiaye<sup>4</sup>, Ngayo Sy<sup>9</sup>, \*Pardis C. Sabeti<sup>1,7,8,10</sup>, \*Daouda Ndiaye<sup>4</sup>, \*Katherine J. Siddle<sup>1,11</sup>

## Affiliations

<sup>1</sup>Broad Institute of Harvard and MIT, Cambridge, MA, USA.

<sup>2</sup>Harvard Graduate Program in Biological and Biomedical Science, Boston, MA, USA.

<sup>3</sup>Harvard/MIT MD-PhD Program, Boston, MA, 02115, USA.

<sup>4</sup>Centre International de recherche, de formation en Génomique Appliquée et de Surveillance Sanitaire (CIGASS), Dakar, Senegal.

<sup>5</sup>University of Massachusetts Medical School, Worcester, MA, USA.

<sup>6</sup>Programme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé, Dakar Fann, Senegal.

<sup>7</sup>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.

<sup>8</sup>Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA. <sup>9</sup>Service de Lutte Anti Parasitaire, Thies, Senegal.

<sup>10</sup>Howard Hughes Medical Institute, Chevy Chase, MD, USA.

<sup>11</sup>Department of Molecular Microbiology and Immunology, Brown University, Providence, RI, USA.

\*Corresponding authors

## 1 Abstract

#### 2

3 The worldwide decline in malaria incidence is revealing the extensive burden of non-4 malarial febrile illness (NMFI), which remains poorly understood and difficult to diagnose. To 5 characterize NMFI in Senegal, we collected venous blood and clinical metadata from febrile

6 patients and healthy controls in a low malaria burden area. Using 16S and unbiased

- 7 sequencing, we detected viral, bacterial, or eukaryotic pathogens in 29% of NMFI cases.
- 8 Bacteria were the most common, with relapsing fever *Borrelia* and spotted fever *Rickettsia*
- 9 found in 15% and 3.7% of cases, respectively. Four viral pathogens were found in a total of 7
- 10 febrile cases (3.5%). Sequencing also detected undiagnosed *Plasmodium*, including one
- 11 putative *P. ovale* infection. We developed a logistic regression model to distinguish *Borrelia*

12 from NMFIs with similar presentation based on symptoms and vital signs. These results

- 13 highlight the challenge and importance of improved diagnostics, especially for Borrelia, to
- 14 support diagnosis and surveillance.

#### 15 Main text

16

#### 17 Introduction

18 Febrile illness is a significant cause of morbidity and mortality in West Africa. While 19 malaria remains the most common single pathogen causing febrile illness, its incidence has 20 decreased sharply in the last two decades; in Senegal, for example, control measures 21 decreased malaria incidence from 122 per 1000 in 2006 to 59 per 1000 in 2021<sup>1,2</sup>. As the 22 malaria burden has decreased, the importance of non-malarial febrile illness (NMFI) has 23 become more apparent. Unlike malaria, however, many of the pathogens causing NMFI are not 24 the target of robust surveillance programs, and rapid diagnostic tests (RDTs), the backbone of 25 both clinical care and surveillance, are not available<sup>3</sup>.

26 A broad range of pathogens across kingdoms can cause NMFI, but surveillance studies 27 often focus on one or a few pathogens and therefore are limited in their ability to detect all 28 causes of disease. Causal pathogens include arboviruses, such as Dengue virus and 29 Chikungunya virus, which cause both sporadic febrile illness and outbreaks in Senegal<sup>4,5</sup>. 30 Bacterial pathogens are a common cause of severe illness requiring hospitalization, including 31 several vaccine-preventable illnesses such as Streptococcus pneumoniae and Neisseria 32 meningitidis<sup>6</sup> and bacterial zoonoses are increasingly recognized as a common cause of 33 ambulatory febrile illness, including tick and louse-borne relapsing fevers, spotted fever, Q fever, Leptospirosis and Brucellosis<sup>6-8</sup>. While fungal infections appear less common, *Candida* 34 and Crvptococcus have been reported across West Africa, with cryptococcal disease being 35 particularly common in HIV-positive patients<sup>6</sup>. Non-malarial parasitic diseases including 36 37 trypanosomiasis and leishmaniasis are also common<sup>6</sup>.

38 In the absence of comprehensive surveillance efforts that capture multiple pathogen 39 types, appropriate public health interventions are hindered by our limited understanding of the 40 full landscape of common causes of NMFI in the region. Unbiased sequencing, also known as 41 metagenomic sequencing (mNGS), is a powerful tool for detection of microbial nucleic acids in clinical samples without a priori knowledge of a pathogen<sup>9</sup> and is increasingly used for 42 surveillance in regions at high risk of emerging and reemerging disease<sup>10–13</sup>. However, the low 43 44 abundance of pathogen nucleic acids relative to host and commensal microbial material requires deep sequencing and can lead to false conclusions<sup>14,15</sup>. Unbiased approaches are 45 complemented by more targeted strategies, such as 16S sequencing for bacterial pathogens<sup>16</sup>, 46 47 that specifically amplify pathogen nucleic acids reducing required sequencing depth and 48 simplifying interpretation. This technique has been applied to detect bacterial bloodstream infections<sup>17,18</sup> and tick-borne bacterial illness<sup>19</sup>. 49

50 This study aimed to determine and characterize the major causes of NMFI in Thiès, 51 Senegal, a peri-urban community with overall low malaria incidence where malaria transmission dynamics have been deeply characterized<sup>20</sup>. We collected plasma samples from a cohort of 52 acutely febrile patients presenting to the Service de Lutte Anti Parasitaire (SLAP) clinic and 53 54 healthy controls from the surrounding neighborhoods during the dry and rainy seasons of 2018 55 and 2019. We aimed to provide insights on clinical presentations of NMFI that can guide 56 providers at the point of care and genomic characterization to inform design of new detection 57 tools for clinical diagnosis and public health surveillance.

58

#### 59 Results

#### 60 Broad characterization of NMFI reveals viral, bacterial, and eukaryotic pathogens

We first comprehensively characterized the pathogens in plasma samples collected from 61 acutely febrile patients suspected of malaria and healthy controls across the dry (febrile: n = 62 63 100, healthy: n = 54) and rainy (febrile: n = 104, healthy: n = 50) seasons in 2019 (Fig. 1A, 64 Supplementary Fig. 1B). All febrile patients received a malaria RDT; 39.4% (41/104) of patients tested positive for malaria in the wet season and no cases were detected in the dry season. 65 66 Febrile cases were roughly equally split between children and adults (50.4% >= 18yrs). Age 67 distribution was similar (p = 0.98, Mann-Whitney, two-sided) across case and control groups, but there were more male febrile cases (Male: n = 110, Female: n = 91) and more female 68 controls (Male: n = 47, Female: n = 57, p = 0.15 Fisher exact two-sided, Supplementary Fig. 1A). 69

70 We performed broad detection of viral, bacterial, and eukaryotic pathogens by 71 sequencing. To detect viral pathogens, we performed RNA-mNGS. We also evaluated the 72 ability of RNA-mNGS to detect non-viral pathogens, including malaria and fungi. To detect 73 bacterial infections, we sequenced the v1-2 region of the 16S rRNA gene, which permitted us to 74 classify the bacterial taxa present in samples with high bacterial load [see methods]. We 75 detected at least one pathogen in 24% (39/163) of RDT-negative acutely febrile patients and co-76 infections in 7% (3/41) of RDT-positive acutely febrile patients (Fig. 1B). The most common 77 febrile pathogen was *Borrelia*, which was found across the dry (n = 8) and rainy (n = 10)78 seasons and in both RDT-negative (n = 17) and RDT-positive (n = 1) patients. We also detected 79 bacterial infections with Rickettsia. Arcobacter. Actinomyces and Brevibacterium (Fig. 1D). Bacterial pathogens found as co-infections included three Borrelia/Rickettsia co-infections, two 80 81 Borrelia/Plasmodium co-infections, and three Plasmodium/Rickettsia co-infections (Fig. 1E).

82 We identified four known vertebrate viruses, Dengue virus (DENV, n = 2), Hepatitis B 83 virus (HBV, n = 2), Parvovirus B19 (n = 2), and Human immunodeficiency virus 1 (HIV-1, n = 1) 84 as well as a human virus not currently believed to cause disease, Pegivirus C (GBV-C, n = 4) (Fig. 1C). Four febrile patients and one healthy control exhibited a high proportion of fungal RNA 85 86 reads in the plasma, as compared to healthy controls (> 99th percentile reads/million raw reads 87 (rpm) for healthy controls), but these reads did not map to any specific fungal pathogen (Supplementary Fig. 8A). We did not detect any vertebrate viruses in healthy controls, but we 88 did detect *Borrelia* (n = 1/35 samples sequenced) and *Rickettsia* (n = 1/35). 89

90

#### 91 RNA-mNGS identifies viral pathogens known to circulate in Senegal

92 We next considered the genetic diversity of detected viral pathogens to determine their 93 relationship to other circulating strains in West Africa. Phylogenetic analysis of complete DENV. 94 HBV and Parvovirus B-19 genomes indicated that in all three cases, the two isolates were 95 different genotypes, and thus not closely related (Supplementary Table 1). Notably, there was a 96 DENV outbreak across Senegal, including Thiès, in 2018. Whole genome phylogenetic analysis 97 revealed the closest relatives to the 2019 DENV3 isolate from this study were DENV3 genomes from patients presenting to the SLAP clinic during that outbreak<sup>4</sup> (Supplementary Fig. 2A). 98 99 Conversely, the DENV1 genome in this study was more closely related to other isolates from 100 West Africa than to the DENV1 isolates from the 2018 outbreak (Supplementary Fig. 2A). The 101 HIV-1 isolate genome could not be assembled and genotyped due to low read count (mean

102 coverage 0.2), but reads mapped across the reference genome including in the *gag, pol,* and
 103 *env* genes.

While GBV-C is known to infect asymptomatic individuals across the world, we only
detected GBV-C in febrile patients. The prevalence of GBV-C has not been well studied in
Senegal; we found infection in only 1.3% (4/307) of plasma samples sequenced, lower than the
4-11% reported in blood-donor surveys from Sub-Saharan Africa<sup>21,22</sup>. All four isolates were
clustered with previously sequenced human isolates from Sierra Leone, Uganda and Cameroon
and belonged to Genotype I (Supplementary Fig. 2B), the most commonly circulating GBV-C
genotype in West Africa<sup>23</sup>.

111 In order to identify divergent viral species missed at the read level, we performed a 112 translated nucleic acid search of de novo contigs which identified RNA-dependent RNA 113 Polymerase (RdRp) sequences for two candidate novel viruses, one in the Naranviridae family 114 and one in the *Reoviridae* family. We detected a *Reoviridae* RdRp sequence across 18 febrile 115 patients, 12 healthy controls, and 4 non-template controls, suggesting a likely contaminant 116 (Supplementary Fig. 3). However, given that *Reoviruses* have been isolated from ill patients, we 117 further investigated these sequences<sup>24</sup>. The *Reovirus* RdRp sequences from this study 118 clustered together, but were distant from mammalian Orthoreoviruses. Given the distance from 119 mammalian Orthoreovirus species and presence in non-template controls, these sequences 120 were likely from a contaminated reagent rather than true human infections. We also identified a 121 Narnaviridae RdRp sequence across 5 febrile patients and 1 healthy control (Supplementary 122 Fig. 4), none of whom had any other identifiable pathogen. Because viruses in the Narnaviridae family, which infect plants and fungi, have not been reported as human pathogens and we 123 124 detected this novel Narnavirus species in both febrile cases and a healthy control, the role of 125 this virus in disease, if any, is unclear.

126

#### 127 Unbiased RNA sequencing detects Plasmodium cases missed by RDT

128 If RNA-mNGS is to be employed as a tool for diagnosis of febrile illness in malaria 129 endemic regions, we also need to understand the ability of RNA-mNGS to detect malaria as 130 compared to clinical diagnostics. We know that RDTs have limited sensitivity, detect only certain 131 *Plasmodium* species, and are susceptible to false negatives in genetically diverse parasites, so 132 we evaluated our RNA-mNGS reads for evidence of *Plasmodium* infections.

133 RNA-mNGS detected abundant Plasmodium nucleic acids (>550 rpm) in 6.8% (11/160) 134 of RDT negative acutely febrile patients, suggesting these were false negatives. Among RDT 135 positive patients, there was a wide range in the abundance of *Plasmodium* reads (mean 136 1.7x10<sup>4</sup> rpm, range 1.5x10<sup>2</sup> - 2.6x10<sup>5</sup> rpm) (Supplementary Fig. 5A). Overall, 63% of RDT 137 positive patients (26/41) and 77% of smear positive patients (17/22) were also positive by 138 unbiased RNA sequencing (>550 rpm) (Supplementary Fig. 5C). In patients with detectable 139 parasitemia by blood smear examination. *Plasmodium* reads did not correlate strongly with 140 parasite density (Pearson's R = 0.49, Supplementary Fig. 5B).

- 141 In order to determine why 11 samples were negative by RDT but positive by RNA-142 mNGS, we first determined whether any samples belonged to species other than *Plasmodium* 143 *falciparum*, the target species of the RDTs (Bioline Malaria Ag P.f., Abbot). As previous work 144 has demonstrated Kraken2 is inaccurate for species-level classification of parasites<sup>25</sup>, we used
- 145 DIAMOND to identify one sample with a contig (771 bp) that matched perfectly (100%

146 nucleotide identity, 100% coverage) to *Plasmodium ovale* cytochrome oxidase subunit 1

147 (Accession: KP050416.1), suggesting a likely *P. ovale* infection. Additionally, we assessed

- 148 expression levels of histidine-rich protein 2 (HRP-2), the target antigen of the RDTs used in this
- study. Deletions in *pfhrp2* gene have been detected in Senegal and demonstrated to cause
- 150 decreased antigen expression and consequently false negative RDT results<sup>26,27</sup>. The number of
- 151 RNA-mNGS rpm aligned to *pfhrp2* was significantly different between patients who were RDT
- 152 positive and mNGS positive (RDT+/mNGS+) and patients who were RDT negative but
- 153 Plasmodium RNA-mNGS positive (RDT-/mNGS+) (Supplementary Fig. 5D, Mann Whitney two-
- sided, p = 0.038). However, given the overlap in expression levels between the two groups and the low frequency of *pfhrp2* deletion in Senegal, previously estimated at 2.4%<sup>27</sup>, *pfhrp2* deletion
- 156 likely explains only some of the false negative RDTs.
- 157
- 158 16S sequencing confirms a high burden of Relapsing Fever Borrelia and Spotted Fever
   159 Rickettsia

160 As bacteria were the most common cause of NMFI in our 2019 cohort, we extended our 161 16S sequencing to detect bacterial infections across the complete cohort from 2018-2019, and 162 further investigated the species causing disease. Among all high bacterial load samples that 163 underwent 16S sequencing [see methods], we detected Borrelia in 15.5% (33/213) and 164 Rickettsia in 5.1% (9/213) of febrile patients. These arthropod-borne bacterial pathogens are 165 known to circulate in Senegal and cause febrile illness (Fig. 1D, Supplementary Fig. 6C)<sup>8</sup>. 16S 166 sequencing also identified other bacterial genera containing known pathogens, including 167 Bacteroides, Actinomyces, Brevibacterium, Arcobacter and Veillonella across both years 168 (Supplementary Fig. 6C). However, given the limited taxonomic resolution of v1-2 16S 169 sequencing, we were unable to determine whether these sequences represented pathogenic 170 species or harmless commensals.

171 Phylogenetic clustering of Borrelia v1-2 16S sequences showed that all Borrelia 172 sequences from this study were similar to each other and fell within the Relapsing Fever (RF) 173 group (Supplementary Fig. 7A). RF Borrelia circulate worldwide and are known to cause febrile 174 illness in Senegal<sup>28</sup>. All the *Rickettsial* v1-2 16S rRNA gene sequences clustered within the 175 Spotted Fever group (Supplementary Fig. 7B). Spotted fever *Rickettsia*, including *R. felis*<sup>29</sup> and *R. africae*<sup>8</sup> have been previously detected in febrile Senegalese patients. We did not detect any 176 177 Typhus group *Rickettsia* in our cohort, though *R. typhi* has been reported in an immigrant 178 traveling from Senegal<sup>30</sup>.

A subset of 6 *Borrelia* isolates were typed by amplicon sequencing of the 16S-23S intergenic spacer (IGS)<sup>31</sup>. All typed isolates were *Borrelia crocidurae* (Fig. 2C). Isolates from this study were more similar to previously characterized isolates from humans and *Orthnithodoros sonrai* in Southern Senegal (unpublished) and *Orthnithodoros sonrai* ticks in Mali<sup>32</sup> than isolates from *Orthnithodoros erraticus* in Tunisia<sup>33</sup> and Morocco<sup>34</sup> (Fig. 2C).

184

# 185 **16S sequencing enables detection of low-titer infections**

We assessed the ability of RNA-mNGS to detect bacterial infections, based on samples that underwent both sequencing methods. *Borrelia* RNA-mNGS reads were detected in 68% (13/19) of 16S positive samples. Conversely, *Rickettsia* RNA-mNGS reads were not detected in any *Rickettsia* positive samples. Acute RF *Borrelia* infection is known to cause high titers of

bacteria in the blood during febrile episodes, while *Rickettsia* is an obligate intraerythrocytic

- 191 pathogen and therefore has low titers in the plasma. To assess the extent to which plasma titers
- 192 impacted the sensitivity of RNA-mNGS to tick-borne bacterial pathogens, we quantified bacterial
- abundance by the percent of total v1-2 16S sequences from a given sample classified as
- 194 *Borrelia* or *Rickettsia*, respectively<sup>19</sup>. We observed *Borrelia* abundances ranging from 5-98%,
- 195 while *Rickettsia* abundances were lower, ranging from 5% to 16%. RNA-mNGS only detected
- Borrelia in samples with abundance >20% (Supplementary Fig. 7F). Taken together, these data
- 197 suggest that RNA-mNGS can detect high titer bacterial pathogens but will miss less abundant198 species.
- 199 We compared the sensitivity of our 16S sequencing to qPCR and Giemsa stained blood 200 smear examination, the current gold standard for clinical diagnosis of RF Borrelia<sup>35</sup>. We 201 examined smears from a subset of RF Borrelia patients. 28.6% (4/14) of examined smears were 202 positive; all 4 positive patients had a high RF Borrelia load (>= 90%, Mann-Whitney two-sided p 203 = 0.002 compared to 16S positive/smear negative) (Supplementary Fig. 6B, D). Although blood 204 smear examination is the most widely used diagnostic, gPCR diagnostics are known to have 205 higher sensitivity<sup>35,36</sup>. Using a pan-*Borrelia* qPCR assay previously used for detection of *Borrelia* in patient blood samples<sup>37</sup> 79% (27/34) of *Borrelia* samples were confirmed by gPCR, while 6 206 207 samples that were negative by 16S sequencing were positive by qPCR. Bacterial load 208 measured by qPCR and 16S abundance correlated well (Pearson's R = 0.72, Supplementary 209 Fig. 6G). While 16S sequencing was done only on a subset of samples, pan-Borrelia gPCR was 210 performed on all febrile cases and healthy controls in 2019 and all febrile cases in 2018. An 211 additional 5 cases of Borrelia were identified in febrile patients by qPCR in samples that did not 212 undergo 16S sequencing (Supplementary Fig. 7E).
- 213

# Borrelia infection presents similarly to other febrile illness but can be distinguished by key features

216 Given the limited sensitivity of available smear-based diagnostics compared to molecular 217 methods, we sought to assess the clinical syndrome associated with qPCR-confirmed Borrelia 218 infections, compared to RDT-confirmed malaria and non-Borrelia NMFI ("other febrile"), to guide 219 differential diagnosis at the point of care. Borrelia infections occurred in a consistent proportion 220 of the study population in the two years (Fisher exact p = 0.61) and in both seasons (Fisher 221 exact p = 0.24). Borrelia infections occurred across all ages (t-test compared to all other febrile 222 p = 0.45) (Fig. 2B) and at similar rates in male and female patients (Fisher exact p = 0.87), while 223 male patients were more likely to test positive for malaria (Fisher exact p = 1.6e-7).

224 A high proportion of *Borrelia* positive patients reported generalized symptoms that were 225 common across all febrile patients, including headache (100%), body aches (59%), and 226 dizziness (46%), as reported in previous studies of RF *Borrelia* (Fig. 3A)<sup>36</sup>. *Borrelia* infection 227 was distinguished by vomiting (49%), vomiting was observed more often in Borrelia-positive 228 patients (stat = 2.8, p = 0.0026, Fisher Exact two-sided). Borrelia-positive patients were less 229 likely than other febrile patients to report sore throat (7.7%, stat = 0.21, p = 0.0039, Fisher Exact 230 two-sided). Notably, RF Borrelia can invade the central nervous system in severe cases: while 231 we did not observe neurological symptoms such as seizures or loss of consciousness, one 232 Borrelia positive patient reported eye pain, a potential symptom of neuroinvasive infection not observed in any other febrile patients<sup>36,38</sup>. A high proportion of *Borrelia*-positive patients reported 233

contact with a febrile person (38%), contact with rats (57%), and prior travel (32%), but these
exposures were common across malaria and other febrile patients and were not associated with *Borrelia* infection in particular (Fig. 3B).

Borrelia patients showed significant differences in temperature and blood glucose. On average, Borrelia positive patients had a higher fever (mean =  $38.6^{\circ}$ C, SD =  $1.1^{\circ}$ C) than other febrile patients (mean =  $38.0^{\circ}$ C, SD =  $1.0^{\circ}$ C, Mann-Whiteny two-sided p = 0.0011). Borrelia patients (mean = 1.07 g/L, sd = 0.19) were also hypoglycemic compared to other febrile patients (Other febrile: mean = 1.22 g/L, sd = 3.97, Mann-Whiteny two-sided p = 1.204e-02) (Fig. 3C).

242 We assessed whether the addition of a complete blood cell count with differential could 243 help distinguish RF Borrelia from other febrile diseases. Borrelia positive patients exhibited 244 abnormal blood counts, including lymphopenia (mean 1.5 x 10<sup>9</sup> cells/L, std 1.04), 245 granulocytosis (mean 7.47 x 10<sup>9</sup> cells/L, std 4.23), and thrombocytopenia (148 x 10<sup>9</sup> cells/L 246 std 66) (Fig. 3D). However, this hematologic response was not significantly different from the 247 response observed in other febrile patients. On a subset of patients, we measured 23 cytokines 248 and chemokines to further distinguish Borrelia from other infections (Fig. 3E). Borrelia positive 249 patients were distinct from viral infections in elevated CRP (Mann-Whitney two-sided, p = 250 (0.030), IL-10 (p = 0.00038), and MIP-1Beta (p = 0.0049) and decreased IP-10 (p = 0.00070), 251 IFN-alpha (p = 0.0022), and MCP-1 (p = 0.00038) (Fig. 3E).

252 Given the highly overlapping presentation of disease, we developed a weighted logistic 253 regression model to distinguish *Borrelia* infection from other NMFI based on clinical symptoms, 254 vital signs, and key demographic information. We evaluated the performance of the model with 255 bootstrapping and found the model was able to predict Borrelia infection with high performance 256 (recall: 0.861, 95% CI [ 0.837 - 0.910], precision: 0.792, 95% CI [ 0.696 - 0.892], and F1-score: 257 0.823, 95% CI [0.766 - 0.900]) (Fig. 4A). The model identified features that were significant in 258 univariate analysis, including vomiting, temperature, blood glucose, and sore throat. 259 Interestingly, common symptoms that were observed across all febrile patients, such as 260 headache, body ache, and dizziness were not useful predictors on their own but were 261 associated with increased risk of Borrelia when evaluated in the context of other symptoms and 262 exposures. To test whether additional laboratory tests might further increase performance of the 263 model, we incorporated complete blood count with differential (CBC) values. The addition of 264 CBC values moderately increased model performance (Supplementary Fig. 9), but the 265 difference was not significant and the test dataset was small (n = 163). When blood biomarkers 266 were incorporated, decreased platelet count was an important predictor of Borrelia.

267

## 268 Discussion

269 In this study, we employed untargeted RNA-mNGS and targeted 16S sequencing to 270 understand the causes of acute febrile illness at an ambulatory clinic in Thiès, Senegal. As the 271 first unbiased investigation of causes of fever in Senegal, our findings highlight the importance 272 of looking across many pathogen types simultaneously to understand their contributions-both 273 individually and as co-infections-to disease, and enable comparison of the strengths of 274 genomic tools as well as clinical and epidemiological data to support disease characterization. 275 Arthropod-borne bacterial pathogens, Borrelia and Rickettsia, are the major identifiable 276 causes of NMFI, but remain underdiagnosed. The frequency of these pathogens is broadly consistent with previous findings in targeted studies from other regions of Senegal<sup>8,39</sup>. Borrelia 277

spp. associated with human and zoonotic infection have been identified in ticks across West
 Africa<sup>28,36,40,41</sup> but human surveillance has not been done.

Our unbiased approaches and broad sampling illuminated co-infections and missed
 diagnoses that may be clinically relevant. Both *Borrelia* and *Rickettsia* occurred frequently as
 co-infections in our study. *Rickettsia* was detected more often as a co-infection with
 *Plasmodium* (n = 3) or *Borrelia* (n = 2) than as a stand-alone infection (n = 3).
 *Borrelia/Plasmodium* co-infections have been previously detected in Senegal<sup>42</sup> and *in vitro*

285 evidence suggests co-infection increases the risk of severe malarial illness<sup>43</sup>. *Plasmodium/R*. felis co-infections have been previously identified in Senegal<sup>44</sup> and Anopheles gambaie, the 286 287 primary malaria vector in Senegal, may be able to transmit *Rickettsia*<sup>45</sup>. Whether *Rickettsia* is 288 contributing to pathogenesis or simply co-transmitting in these cases remains an open question. 289 More research is needed to understand the interaction between the parasite and *Rickettsia* 290 species. Given the common occurrence of co-infections and potential for negative outcomes 291 without proper treatment of both pathogens, it is important that both surveillance and diagnostic 292 approaches do not stop at detection of the first pathogen.

293 Despite using multiple methods and searching across kingdoms, we did not find any 294 pathogen in over 70% of NMFI cases in this study. Although our enrollment criteria focused on 295 suspicion of malaria, many of these patients reported sore throat and difficulty breathing (2019: 296 35%, 40/113) or abdominal pain (4.4%, 5/113). Given that only plasma samples were collected 297 and sequenced, our approach may have missed infections limited to other body compartments, 298 including the respiratory tract and digestive tract. Our results also demonstrate the difficulty of 299 using RNA-mNGS to detect DNA pathogens and pathogens with different cellular compositions. 300 Several of the bacterial infections in this cohort, particularly those with low abundance in the 301 blood, were detected by 16S but missed by RNA-mNGS. Similarly, we were not able to resolve 302 putative fungal hits to a suitable level of taxonomic resolution; to capture fungal pathogens, 303 extraction methods should be optimized for lysis of fungal cells and more targeted methods 304 such as ITS sequencing could be used. We observed wide variations in the number of 305 *Plasmodium* reads among RDT positive patients and weak correlation with parasite density, 306 suggesting that factors beyond parasite burden affect the number of reads recovered. There are 307 also still many challenges in interpreting the RNA-mNGS data. In particular, RNA-mNGS is 308 highly susceptible to contamination, such as the novel Reoviridae RdRp sequences we detected 309 across febrile cases, healthy controls and non-template controls. Negative controls should be 310 included alongside samples throughout processing to measure the "contaminome," which likely 311 differs between sample types and labs<sup>15</sup>.

312 We find that combinations of clinical signs and symptoms can increase suspicion for 313 Borrelia and support targeting clinical care. Due to the lack of available point-of-care tests, many clinics in LMICs rely on malaria RDTs as the primary diagnostic for febrile illness and may give 314 blanket antibiotic treatment to RDT-negative patients<sup>46</sup>. Concerns have been raised about this 315 practice<sup>47</sup>, including driving antibiotic resistance and exposing patients to unnecessary risks or 316 317 side effects. For example, tetracycline antibiotic treatment—the recommended therapeutic for 318 Borrelia and Rickettsial infections-poses the risk of Jarich-Herxheimer reaction (JHR), a 319 severe inflammatory response to spirochete lysis that often requires close patient monitoring<sup>48</sup>. 320 We identify a number of clinical and immunological features that could bolster support for a 321 Borrelia diagnosis. Our weighted logistic regression model indicates that when larger cohorts

322 and diverse data types are aggregated, Borrelia can be differentiated from other NMFI with 323 reasonable accuracy. The addition of laboratory measures, such as CBC, did not substantially improve differential diagnosis. Further, data from a subset of our cohort supports the hypothesis 324 325 that a chemokine panel including TRAIL, IP-10 and CRP, previously employed for detection of bacterial infections in hospitalized children<sup>49</sup>, could apply more broadly and help distinguish 326 327 bacterial infections such as Borrelia from other causes of febrile illness in the ambulatory 328 setting. However, none of these approaches are currently actionable as point-of-care tests and 329 their lower precision would still necessitate confirmatory diagnostic testing.

330 The challenge of guickly and accurately differentiating Borrelia infections underscores 331 the need for improved diagnostics. The diagnostic gold standard for Borrelia remains 332 microscopic examination of blood smears, which has low sensitivity in our study and others<sup>35</sup>. 333 Further, smear cannot distinguish species, and is highly dependent on a trained practitioner. 334 Our study showed that molecular methods, including 16S sequencing and mNGS, can detect 335 Borrelia infections, but are not practical in the clinical setting. Increased availability of gPCR 336 assays and improved point of care nucleic acid diagnostics could enable detection and 337 treatment of Borrelia across differently resourced clinical settings and improve our 338 understanding of the geographic range and diversity of this pathogens

339 An increasingly heterogeneous pathogen landscape will require the integration of 340 targeted diagnostics and broad surveillance to effectively combat acute febrile infections moving 341 forward. Decreased malaria transmission coupled with changes in the range and incidence of 342 other pathogens-influenced in part by global climatic shifts-is broadening the array of pathogens accounting for the majority of febrile disease<sup>50</sup>. Fully understanding this landscape 343 344 will require surveillance systems utilizing unbiased approaches that have been validated for 345 viral, bacterial and eukaryotic pathogens and diverse sample types. In tandem, for Borrelia and 346 other pathogens known to frequently cause NMFI, the development and availability of diagnostic 347 tests that are cheap, rapid and sensitive will be key to enable appropriate clinical treatment at 348 the point of care and support deeper investigations of the pathophysiology of disease. 349

#### 350 Methods

#### 351 Sample collection

352 Febrile cases were selected from patients presenting to the SLAP outpatient clinic in 353 Thies, Senegal during the collection period under local IRB (SEN15/46) and Harvard IRB 354 (IRB19-0023). Informed consent was obtained for all enrollees; for minors under 18 years of age 355 or individuals unable to provide their own consent, the consent of a parent or legal guardian was 356 obtained. The study team explained to potential participants that their participation was strictly 357 voluntary and that they could withdraw from the study at any time without any penalties or 358 consequences and translations were made for potential participants (or their parent / legal 359 guardian) that do not understand or cannot read the language in which the consent form was 360 produced.

Patients who met the following inclusion criteria and gave consent were enrolled: (1) Febrile symptoms within the 3 days up to and including the day of presentation, (2) Age 2-75 years, and (3) Ambulatory with no signs of severe malarial (glucose < 2.2mM, hemoglobin < 5 gms/dL). A subset of DENV positive samples from 2018 were previously sequenced and published<sup>4</sup> and were excluded from this study other than being used as a viral outgroup in the

chemokine/cytokine analyses. At the time of enrollment, a structured interview including
personal information, demographics, and self-reported symptoms was completed, vital signs
were measured and blood was drawn by a trained practitioner. *Plasmodium falciparum* RDT
(Bioline Malaria Ag P.f., Abbott), thick blood smear, and thin blood smear was performed and
blood glucose (HemoCue 201/301) and hemoglobin (HemoCue Glucose 201) were measured.

371

## 372 Sample processing

373 Blood samples were stored on ice upon collection (maximum 8 hours). In the lab, blood 374 samples were split into two aliquots. 200 ul of the first aliquot was used for an automated blood 375 count with differential (Mindray BC 20s) and 200uL was used for a blood spot (Whatman filter 376 paper) The remaining aliguot was centrifuged at 2300 rpm for 10 min to separate plasma, buffy 377 coat and red blood cells. 140 uL of plasma was transferred to a tube containing 760uL of 378 inactivation buffer (AVL, Qiagen). The remaining plasma was stored without inactivation. Red 379 blood cells, buffy coat, plasma, and inactivated plasma were flash frozen and stored at -80°C 380 until further processing. Total nucleic acids were extracted with Qiagen QIAmp Viral Mini RNA 381 according to the manufacturer's protocol. Total nucleic acids were split into two aliquots and 382 treated with Lucigen RNAse I or Ambion TURBO DNase to obtain purified DNA and RNA. 383 respectively.

384

## 385 Unbiased RNA sequencing

## 386 Library preparation and sequencing

387 Unbiased RNA sequencing libraries were prepared as described previously<sup>51</sup>. Briefly, 388 cDNA synthesis was performed from DNAse-treated RNA using random hexamers (Illumina) 389 and SSIV. Libraries were prepared from cDNA using Nextera XT (Illumina) and UD index 390 primers (IDT/Illumina) with the following modifications to account for low cDNA input: the volume 391 of ATM was decreased from 1uL to 0.5uL per 10uL reaction and PCR cycles were increased to 392 17 cycles. Libraries were purified using AMPure XP (Agilent), guantified using KAPA 393 Biosystems Universal Library Quantification, and pooled equally for 75bp paired end 394 sequencing on NovaSeg SP to obtain at least 2 million reads per sample.

395

## 396 Taxonomic classification of RNA-mNGS reads

Unbiased RNA sequencing reads were processed using viral-ngs<sup>52</sup>. Briefly, reads were
demultiplexed, adapter sequences were trimmed, and sliding-window quality filtering was
performed. Human reads were filtered out using BMTAGGER and BLASTN. Cleaned reads
were uploaded to NCBI SRA under BioProject PRJNA662334 (Accession numbers:
SRR24622550-SRR24622641, SRR24995052-SRR24995258). Samples with insufficient reads
(<2 million) were removed from further analysis (n = 1, SHC1064, Accession: SRR24995248).</li>

403

Taxonomic classification of human-depleted reads was performed using Kraken2<sup>53</sup> with the JHU PlusPF database (JHU, downloaded 12-13-2022). Kraken2 results were thresholded to consider only viral genera with at least 5 reads/million raw reads. Results were filtered to remove viral taxa detected in non-template controls (at least one non-template control) and healthy patients (at least 2 healthy patients). Further, viral genera with non-vertebrate hosts were filtered out.

To verify Kraken2 classifications, we performed a protein-sequence similarity search using DIAMOND-blastx<sup>54</sup>. Cleaned, de-duplicated reads were used for *de novo* contig assembly with SPAdes and DIAMOND-blastx was run on all *de novo* contigs > 100 bp long with the complete nr database (downloaded December 2022). The least common ancestor of the top e-value hits was identified using a custom script (lakras/bio-helper-

415 scripts/blast/retrieve\_top\_blast\_hits\_LCA\_for\_each\_sequence.pl). A classification was

416 considered verified by DIAMOND if the cumulative length of contigs with a high identity match

417 (mean identity of top e-value hits >= 95%) to the expected viral genus was at least 1kb. After

- 418 DIAMOND-blastx verification, raw reads were aligned to the NCBI Virus RefSeq and assessed 419 for evenness and depth of coverage.
- To assess for presence of divergent viral taxa that are not well represented in the database and may be missed by Kraken2, DIAMOND-blastx results were filtered for viral hits with low identity (20-80% amino acid identity). Results were filtered for viral families with a persample cumulative *de novo* contig length >= 500 bp. *Narnaviridae* and *Reoviridae* sequences were aligned with all available RdRp sequences for each family in nr using MAFFT and trimmed with trimAl. Maximum likelihood phylogenetic trees were generated in IQ-TREE<sup>55</sup> with a GTRgamma substitution model and bootstrapping (n = 1000) and visualized in FigTree v1.4.4<sup>56</sup>.
- 427

## 428 Viral genome assembly and phylogenetic analysis

429 For virus-positive samples, reference-guided *de novo* assembly was performed using 430 viral-ngs (assembly with SPAdes, reference-assisted improvements with MUMMER and 431 MUSCLE/MAFFT and gap sealing with Gap2Seq). The NCBI Virus RefSeq as well as any 432 >80% complete genomes available from Senegal were provided as references. For samples 433 with near-complete or complete (>80%) genomes, genotype was determined with 434 GenomeDetective (DENV, HBV) or by phylogenetic tree (Parvovirus B-19, GBV-C). 435 Phylogenetic trees were generated with all >80% complete references from Africa downloaded 436 from NCBI viruses (DENV1, DENV3, HBV), or all global >80% complete genomes available in 437 NCBI virus (Parvovirus B-19, GBV-C). Sample sequences and reference sequences were aligned using MAFFT v7<sup>57</sup> and alignments were trimmed with trimAl v1.4.rev15<sup>58</sup> to remove any 438 439 bases with coverage in <80% of sequences. Maximum likelihood phylogenetic trees were

generated in IQ-TREE<sup>55</sup> with a GTR-gamma substitution model and bootstrapping (n = 1000).

441 Visualizations were generated with FigTree v1.4.4<sup>56</sup>.

442

# 443 Plasmodium RNA-mNGS analysis

In order to quantify *Plasmodium* rpm, the number of reads classified as *Plasmodium* at
the genus level by Kraken2 was divided by the raw read count in millions. The cut-off for
considering a sample positive for *Plasmodium* by mNGS was determined by calculating the 99th
percentile for healthy control samples, 550 *Plasmodium* rpm. Cleaned deduplicated reads were
aligned to the *P. falciparum pfhrp2* (PlasmoDB PF3D7\_0831800) with NovoAlign.

449450 Fungal RNA-mNGS analysis

In order to detect possible fungal infections, we calculated the rpm classified as Fungi by
Kraken2<sup>53</sup> at the kingdom level and determined the 99th percentile for healthy controls, 3399
rpm. We identified 5 samples (4 febrile, 1 control) with high fungal reads. We attempted

454 taxonomic classification of these reads with Kraken2 at the genus level and saw hits across

455 multiple genera for many samples (Supplementary Fig. 8B). To try to improve fungal

456 classification, we performed a nucleic acid search of all *de novo* contigs from these 5 samples

457 with megablast against nt (Supplementary Fig. 8C) and a translated nucleic acid search with

458 DIAMOND-blastx<sup>54</sup> (as described above). For both searches, we found the least common

459 ancestor of the top hits (as described above), and filtered hits in the kingdom Fungi (taxid: 4751)

with >90% identity and >30% coverage.

# 462 **qPCR**

Total bacterial load was quantified from extracted plasma DNA with primers targeting the V1-2 region (see Supplementary Table 2 for primer sequences) with Power SYBR Green PCR MasterMix (Thermo Fisher) under the following conditions: 300nM each F/R primer, 95°C hold for 10 min, 40 cycles of 95°C for 15 sec, 50°C for 1 min, 75°C for 30s. Pan-*Borrelia* qPCR was performed with Power SYBR Green PCR MasterMix (Thermo Fisher) under the following conditions: 400 nM each F/R primer, 95°C hold for 10 min, 40 cycles of 95°C for 15 sec, 60°C for 1 min.

#### 470 471 **16S sequencing**

## 472 Library preparation and sequencing

473 Samples with high bacterial load (V1-2 gPCR CT < 31.5) were selected for 16S 474 sequencing (2019: febrile n = 129, healthy n = 35, 2018: febrile n = 84). Libraries were generated by amplification with tailed universal primers Tail-V1-2F and Tail-V1-2R 475 476 (Supplementary Table 2) targeting variable regions 1-2. Amplification was performed on 5ul of 477 RNAse-treated DNA using Q5 high fidelity polymerase (NEB) with forward and reverse primers 478 at 100nM each with the following cycling conditions: 98°C for 30 sec; 35 cycles of 95°C for 15 479 sec and 63°C for 2 min, 4°C hold. PCR products were cleaned using Ampure XP (Agilent) with 0.7X ratio to remove primer dimers. Adapters and barcodes (BroadDuplex Seq) were added 480 481 with a second PCR reaction using Q5 polymerase and the following cycling conditions: 98°C for 482 30 sec; 18 cycles of 95°C for 15 sec, 60°C for 15S, 72°C for 30S, followed by 72°C for 5min, 483 4°C hold. A subset of libraries were visualized with hsDNA BioAnalyzer (Agilent) and all libraries 484 were quantified with KAPA Biosystems Universal Library Quantification Kit before pooling 485 equally across samples and 250 bp paired-end sequencing on Illumina MiSeg v2 with 40% 486 PhiX, given the low diversity of the single-amplicon library.

487

## 488 Analysis

Sequencing reads were demultiplexed using viral-ngs and demultiplexed FASTQ files were imported into qiime2<sup>59</sup> for further analysis. Briefly, after sliding window quality filtering and adapter trimming with cut-adapt (minimum-length 20), paired reads were joined with vsearch (tuncqual 15, minlen 35, minovlen 10, maxdiffs 3), and ASVs were generated with Deblur (trimlength 280). ASVs were taxonomically classified by blastn search of ASV sequences against the NCBI 16S rRNA db (downloaded June 2023). The least common ancestor of the top e-value hits was determined using a custom script (lakras/bio-helper-

496 scripts/blast/retrieve\_top\_blast\_hits\_LCA\_for\_each\_sequence.pl). Abundance was calculated

497 by dividing the number of ASVs in each genus by the total number of ASVs in each sample.

498 Abundance data was filtered to show only taxa accounting for greater than 5% of ASVs. Taxa 499 detected in non-template controls ( $n \ge 1$ ) and healthy controls ( $n \ge 2$ ) were filtered out.

500 For *Borrelia* and *Rickettsia* positive samples, sample ASVs were aligned with MAFFT<sup>57</sup> 501 (Geneious) with curated high-quality 16S sequencing from the NCBI 16S rRNA BioProject 502 (BioProject: 33175) from each genus respectively. Alignments were trimmed with trimAl to 503 remove positions with gaps in >90% of sequences and a maximum-likelihood phylogenetic tree 504 was generated using IQ-TREE<sup>55</sup> with bootstrapping (n = 1000) and annotated with FigTree 505 v1.4.4<sup>56</sup>.

## 507 IGS Sequencing

508 The intergenic spacer (IGS) region was amplified using a nested-PCR. First, the region 509 was amplified from 5uL of extracted DNA with primers targeting the IGS region (IGS-outer F/R, 510 see Supplementary Table 2) using Q5 polymerase and the following cycling conditions: 98°C for 511 30 sec; 35 cycles of 94°C for 30 sec, 66°C for 30S, 74°C for 60s, followed by 74°C for 2 min, 512 10°C hold. After a 0.75X AMPure XP cleanup to remove excess primer, a nested PCR was 513 performed (IGS-inner F/R, see Supplementary Table 2) using Q5 polymerase and the following 514 cycling conditions: 98°C for 30 sec; 30 cycles of 94°C for 30 sec, 67°C for 30S, 74°C for 60s, 515 followed by 74°C for 2 min, 10°C hold. Amplified product was cleaned with AMPure XP (0.75X), 516 visualized with BioAnalyzer TapeStation and bi-directional Sanger sequencing was performed 517 (Azenta). Paired Sanger sequencing traces were analyzed in Geneious to generate a 518 consensus sequenced and aligned with all available reference sequences for B. crocidurae, B. duttonii, and B. recurrentis using MAFFT<sup>57</sup>. A maximum-likelihood phylogenetic tree was 519 520 generated using IQ-TREE<sup>55</sup> and annotated with FigTree v1.4.4<sup>56</sup>.

521

506

## 522 Blood smear examination

523 Thick and thin blood smears were fixed with methanol and stained with 3mL 10% 524 Giemsa for 10 minutes. Stained smears were examined under a brightfield microscope for 525 evidence of *Borrelia*. Slides were first scanned at low (40X) magnification and then at high 526 (100X) magnification with oil immersion to quantify organisms per field (representative image, 527 Supplementary Fig. 6B).

528

## 529 Serology

530 We assessed levels of common cytokines and chemokines using the Luminex platform 531 on plasma from a subset of patients and controls. Specifically, we selected 10 healthy controls and 30 cases representing 10 each with a confirmed diagnosis of; malaria (based on malaria 532 533 RDT administered at enrollment), Borrelia (based on pan-Borrelia qPCR<sup>37</sup>), or viral infection. 534 Samples with a viral infection were all confirmed to have Dengue virus and are a subset of 535 those cases previously described elsewhere<sup>4</sup>. Cases were selected randomly within those 536 meeting each criteria. All samples were collected in 2018. We used the Inflammation 20-Plex 537 Human ProcartaPlex<sup>™</sup> Panel (Invitrogen), according to the manufacturer's instructions. We 538 additionally performed a 2-plex assay for Human IP-10 and TRAIL (using IP-10 and TRAIL 539 ProcartaPlex<sup>™</sup> simplex kits from Invitrogen); two markers previously found to differentiate bacterial infections in hospitalized children<sup>49</sup>, as these were not included on the predefined 540 541 panel. All samples were run in duplicate on a Luminex MAGPIX® instrument in Senegal. We

542 confirmed that standards showed the expected values and calculated the average across543 duplicates, which we report in the text.

544

#### 545 *Multivariate model*

546 We developed a weighted logistic regression model that considered 46 candidate 547 predictors based on clinical symptoms, vital signs, and key demographic information to predict 548 Borrelia infection. Before modeling, the dataset underwent the following preprocessing steps: 549 imputation of missing values with the Multivariate Imputation by Chained Equations (MICE) algorithm from the fancyimpute Python library<sup>60</sup>, one hot-encoding of categorical features, and 550 551 standardization of continuous features using the StandardScaler from the scikit-learn library. 552 Given that normal heart rate varies significantly with age, heart rates were binned and treated 553 as a categorical variable. Heart rate categories were high, low, or normal based on the Pediatric 554 Advanced Life Support guidelines as follows: for age 3-5, normal range 80-120, age 6-11 normal range 75-118, age 12+ normal range 60-100<sup>61</sup>. 555

556 The sample size was relatively small, with 526 patients and only 38 g-PCR confirmed 557 cases of Borrelia infection. Given this inherent class imbalance in the dataset, a combination of 558 techniques was employed to address this challenge. The Synthetic Minority Oversampling 559 Technique (SMOTE) was applied to generate synthetic samples for the minority class (g-PCR confirmed *Borrelia* case)<sup>62</sup>. This technique mitigates class imbalance by interpolating between 560 existing samples and creating synthetic instances of the minority class. During model training, 561 562 class weights were also applied to adjust the influence of each class. The class weights were 563 inversely proportional to the class frequencies, with higher weights assigned to the minority 564 class.

565 A logistic regression model was chosen for its interpretability and ability to estimate the 566 probabilities of class membership. After a univariate screening for statistically significant 567 predictors using chi-squared test (p-value < 0.05), several Feature Selection techniques were 568 applied to construct the final set of predictors in the model. Before training the model, feature 569 importance was assessed using a combination of three different feature selection methods; mutual information classification<sup>63</sup>, Recursive Feature Elimination<sup>64</sup>, and Lasso L1 570 regularization<sup>65,66</sup> to ensure consistent elimination of redundant variables. The selected features 571 572 were used in the final weighted logistic regression model to analyze the performance of Borrelia 573 prediction. The regularization parameter from Lasso was tuned using cross-validation of 574 different alpha values and the best alpha value was used to train the final model and evaluate 575 its performance on the test set.

576 Model performance was evaluated with bootstrapping and 5-fold cross validation to 577 quantify optimism and generalizability. The optimism-corrected metrics include F1-score, 578 precision, recall, area under the ROC curve (AUC-ROC), and area under the precision-recall 579 curve (AUC-PR). Odds ratios and their corresponding confidence intervals for all the model 580 coefficients were calculated to assess the impact of predictor variables on the odds of the 581 outcome. All predictive analyses were conducted using the Python programming language. The 582 scikit-learn library was utilized for preprocessing, model training, and evaluation. Statistical 583 analyses and visualization of odds ratios and confidence intervals were done using the R 584 statistical package.

585

#### 586 Author contributions

According to the CRediT format, author contributions are as follows: Conceptualization: A.B.D.,
A.S.B., Z.C.L., N.S., P.C.S., K.J.S., and D.N.; Methodology: A.B.D., A.S.B., Z.C.L., N.S., P.C.S.,
K.J.S., and D.N.; Software: D.J.P.; Validation: P.C.S., K.J.S., and D.N.; Formal Analysis: Z.C.L,
K.J.S., W.M., and A.C.; Investigation: Z.C.L, A.S., A.G., T.N., M.S., Y.D., A.M., and I.N.; Data

- 591 Curation: J.G., M.Ndiop, D.S.; Writing Original Draft: Z.C.L. Writing Review & Editing: K.J.S.,
- 592 S.F.S., B.M, and P.C.S. with input from all authors; Visualization: Z.C.L., W.M.; Supervision:
- 593 P.C.S., K.J.S., and D.N.; Project Administration: M.F.P., M.Ndiaye.; Funding acquisition: P.C.S.,
- 594 D.N., K.J.S., D.J.P.

#### 595 596 Funding Statement

- 597 Support for this project was provided in part by the National Institutes of Allergy and Infectious
- 598 Diseases through the H3Africa and Center for Research in Emerging Infectious Disease
- 599 programs (U54HG007480, U01HG007480 and U01AI151812 to C.T.H. and P.C.S.), and the
- 600 Genomic Center for Infectious Disease (U19AI110818 to P.C.S.). Z.C.L was supported by the
- National Institute of General Medical Sciences (T32GM007753 and T32GM144273). K.J.S
- received support from the American Society of Tropical Medicine and Hygiene Centennial
- 603 Award. P.C.S. is an investigator supported by the Howard Hughes Medical Institute (HHMI). The
- 604 content is solely the responsibility of the authors and does not necessarily represent the official
- views of the National Institute of General Medical Sciences, National Institutes of Allergy and
- 606 Infectious Diseases, or the National Institutes of Health.

## 607

## 608 Data and Code Availability

- 609 RNA-mNGS short read sequence data have been deposited in NCBI's SRA and Genbank
- 610 databases under BioProject PRJNA662334 Accession numbers SRR24622550-SRR24622641,
- 611 SRR24995052-24995258. 16S v1-2 amplicon sequencing data and assembled viral genomes
- 612 will be deposited shortly under BioProject PRJNA662334, data currently available upon request.
- 613 The Python source code for the multivariate Borrelia prediction model is available at
- 614 github.com/colabobio/borrelia-diagnosis-prediction-models.
- 615

# 616 Acknowledgements

- 617 We thank the Programme National de Lutte contre le Paludisme (National Malaria Control
- Program) for providing malaria surveillance data, and Fama and Astou for support with data
- entry and organization. We thank Lydia Krasilnikova for advice and custom scripts for BLAST
- analysis, and Flavia Negrete for support with data uploads and sharing. We thank Jacob
- 621 Lemieux and Gordon Adams for providing valuable guidance on *Borrelia* sequencing.
- 622

# 623 Competing Interests

- 624 P.C.S. is a co-founder of, shareholder in, and consultant to Sherlock Biosciences, Inc. and
- 625 Delve Bio, as well as a Board member of and shareholder in Danaher Corporation.

#### **References**

- Thwing, J. *et al.* Declines in Malaria Burden and All-Cause Child Mortality following Increases in Control Interventions in Senegal, 2005-2010. *Am. J. Trop. Med. Hyg.* 97, 89– 98 (2017).
- 2. World Bank. Incidence of malaria (per 1,000 population at risk). (2021).
- 3. WHO. Who informal consultation on fever management in peripheral health care settings a global review of evidence and. (2013).
- 4. Gaye, A. *et al.* Genomic investigation of a dengue virus outbreak in Thiès, Senegal, in 2018. *Sci. Rep.* **11**, 10321 (2021).
- 5. Sow, A. *et al.* Chikungunya Outbreak in Kedougou, Southeastern Senegal in 2009-2010. *Open Forum Infect Dis* **5**, ofx259 (2018).
- 6. Maze, M. J. *et al.* The epidemiology of febrile illness in sub-Saharan Africa: implications for diagnosis and management. *Clin. Microbiol. Infect.* **24**, 808–814 (2018).
- 7. Elven, J. *et al.* Non-malarial febrile illness: a systematic review of published aetiological studies and case reports from Africa, 1980-2015. *BMC Med.* **18**, 279 (2020).
- 8. Sokhna, C. *et al.* Point-of-care laboratory of pathogen diagnosis in rural Senegal. *PLoS Negl. Trop. Dis.* **7**, e1999 (2013).
- 9. Gu, W., Miller, S. & Chiu, C. Y. Clinical Metagenomic Next-Generation Sequencing for Pathogen Detection. *Annu. Rev. Pathol.* **14**, 319–338 (2019).
- 10. Ramesh, A. *et al.* Metagenomic next-generation sequencing of samples from pediatric febrile illness in Tororo, Uganda. *PLoS One* **14**, e0218318 (2019).
- 11. Mwakibete, L. *et al.* Metagenomic next-generation sequencing to characterize potential etiologies of non-malarial fever in a cohort living in a high malaria burden area of Uganda. *PLOS Glob Public Health* **3**, e0001675 (2023).
- 12. Jones, K. E. *et al.* Global trends in emerging infectious diseases. *Nature* **451**, 990–993 (2008).
- 13. Oguzie, J. U. *et al.* Metagenomic surveillance uncovers diverse and novel viral taxa in febrile patients from Nigeria. *Nat. Commun.* **14**, 4693 (2023).
- 14. Houldcroft, C. J., Beale, M. A. & Breuer, J. Clinical and biological insights from viral genome sequencing. *Nat. Rev. Microbiol.* **15**, 183–192 (2017).
- 15. Chrisman, B. *et al.* The human 'contaminome': bacterial, viral, and computational contamination in whole genome sequences from 1000 families. *Sci. Rep.* **12**, 9863 (2022).
- 16. Janda, J. M. & Abbott, S. L. 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: pluses, perils, and pitfalls. *J. Clin. Microbiol.* **45**, 2761–2764 (2007).
- 17. Decuypere, S. *et al.* Diagnosis of Bacterial Bloodstream Infections: A 16S Metagenomics Approach. *PLoS Negl. Trop. Dis.* **10**, e0004470 (2016).
- 18. Watanabe, N. *et al.* Detection of pathogenic bacteria in the blood from sepsis patients using 16S rRNA gene amplicon sequencing analysis. *PLoS One* **13**, e0202049 (2018).
- 19. Kingry, L. *et al.* Targeted Metagenomics for Clinical Detection and Discovery of Bacterial Tick-Borne Pathogens. *J. Clin. Microbiol.* **58**, (2020).
- Sy, M. *et al.* Plasmodium falciparum genomic surveillance reveals spatial and temporal trends, association of genetic and physical distance, and household clustering. *Sci. Rep.* **12**, 938 (2022).
- Casteling, A. *et al.* GB virus C prevalence in blood donors and high risk groups for parenterally transmitted agents from Gauteng, South Africa. *J. Med. Virol.* 55, 103–108 (1998).
- 22. Compston, L. I. *et al.* Prevalence of persistent and latent viruses in untreated patients infected with HIV-1 from Ghana, West Africa. *J. Med. Virol.* **81**, 1860–1868 (2009).
- 23. Lauck, M. *et al.* GB virus C coinfections in west African Ebola patients. *J. Virol.* **89**, 2425–2429 (2015).

- 24. Ouattara, L. A. *et al.* Novel human reovirus isolated from children with acute necrotizing encephalopathy. *Emerg. Infect. Dis.* **17**, 1436–1444 (2011).
- 25. Frickmann, H. *et al.* Metagenomic Sequencing for the Diagnosis of Plasmodium spp. with Different Levels of Parasitemia in EDTA Blood of Malaria Patients-A Proof-of-Principle Assessment. *Int. J. Mol. Sci.* **23**, (2022).
- 26. Deme, A. B. *et al.* Analysis of pfhrp2 genetic diversity in Senegal and implications for use of rapid diagnostic tests. *Malar. J.* **13**, 34 (2014).
- 27. Agaba, B. B. *et al.* Systematic review of the status of pfhrp2 and pfhrp3 gene deletion, approaches and methods used for its estimation and reporting in Plasmodium falciparum populations in Africa: review of published studies 2010-2019. *Malar. J.* **18**, 355 (2019).
- 28. Vial, L. *et al.* Incidence of tick-borne relapsing fever in west Africa: longitudinal study. *Lancet* **368**, 37–43 (2006).
- 29. Socolovschi, C. *et al.* Rickettsia felis-associated uneruptive fever, Senegal. *Emerg. Infect. Dis.* **16**, 1140–1142 (2010).
- Ángel-Moreno, A., Bolaños, M., Santana, E. & Pérez-Arellano, J. L. Tifus murino importado de Senegal en un inmigrante viajero. *Enfermedades Infecciosas y Microbiología Clínica* 24, 406–407 (2006).
- 31. Bunikis, J. *et al.* Typing of Borrelia relapsing fever group strains. *Emerg. Infect. Dis.* **10**, 1661–1664 (2004).
- Schwan, T. G. *et al.* Endemic foci of the tick-borne relapsing fever spirochete Borrelia crocidurae in Mali, West Africa, and the potential for human infection. *PLoS Negl. Trop. Dis.* 6, e1924 (2012).
- 33. Bouattour, A. *et al.* Borrelia crocidurae infection of Ornithodoros erraticus (Lucas, 1849) ticks in Tunisia. *Vector Borne Zoonotic Dis.* **10**, 825–830 (2010).
- 34. Diatta, G. *et al.* Epidemiology of tick-borne borreliosis in Morocco. *PLoS Negl. Trop. Dis.* **6**, e1810 (2012).
- 35. Fotso Fotso, A. & Drancourt, M. Laboratory Diagnosis of Tick-Borne African Relapsing Fevers: Latest Developments. *Front Public Health* **3**, 254 (2015).
- 36. Jakab, Á., Kahlig, P., Kuenzli, E. & Neumayr, A. Tick borne relapsing fever a systematic review and analysis of the literature. *PLoS Negl. Trop. Dis.* **16**, e0010212 (2022).
- 37. Kingry, L. C. *et al.* Surveillance for and Discovery of Borrelia Species in US Patients Suspected of Tickborne Illness. *Clin. Infect. Dis.* **66**, 1864–1871 (2018).
- 38. Lim, L. L. & Rosenbaum, J. T. Borrelia hermsii causing relapsing Fever and uveitis. *Am. J. Ophthalmol.* **142**, 348–349 (2006).
- 39. Mediannikov, O. *et al.* Borrelia crocidurae infection in acutely febrile patients, Senegal. *Emerg. Infect. Dis.* **20**, 1335–1338 (2014).
- 40. Trape, J.-F. *et al.* The epidemiology and geographic distribution of relapsing fever borreliosis in West and North Africa, with a review of the Ornithodoros erraticus complex (Acari: Ixodida). *PLoS One* **8**, e78473 (2013).
- 41. Cutler Sally J., Idris Jibrin M., Ahmed Akeem O. & Elelu Nusirat. Ornithodoros savignyi, the Tick Vector of 'Candidatus Borrelia kalaharica' in Nigeria. *J. Clin. Microbiol.* **56**, 10.1128/jcm.00532–18 (2018).
- 42. Diallo, M. A. *et al.* Plasmodium falciparum malaria co-infection with tick-borne relapsing fever in Dakar. *Malar. J.* **16**, 24 (2017).
- 43. Normark, J. *et al.* Maladjusted host immune responses induce experimental cerebral malaria-like pathology in a murine Borrelia and Plasmodium co-infection model. *PLoS One* **9**, e103295 (2014).
- 44. Mediannikov, O. *et al.* Common epidemiology of Rickettsia felis infection and malaria, Africa. *Emerg. Infect. Dis.* **19**, 1775–1783 (2013).
- 45. Dieme, C. *et al.* Transmission potential of Rickettsia felis infection by Anopheles gambiae mosquitoes. *Proc. Natl. Acad. Sci. U. S. A.* **112**, 8088–8093 (2015).

- 46. Hopkins, H. *et al.* Impact of introduction of rapid diagnostic tests for malaria on antibiotic prescribing: analysis of observational and randomised studies in public and private healthcare settings. *BMJ* **356**, j1054 (2017).
- 47. WHO informal consultation on fever management in peripheral health care settings: A global review of evidence and practice. https://www.who.int/publications-detail-redirect/9789241506489.
- 48. Butler, T. The Jarisch-Herxheimer Reaction After Antibiotic Treatment of Spirochetal Infections: A Review of Recent Cases and Our Understanding of Pathogenesis. *Am. J. Trop. Med. Hyg.* **96**, 46–52 (2017).
- 49. Papan, C. *et al.* A host signature based on TRAIL, IP-10, and CRP for reducing antibiotic overuse in children by differentiating bacterial from viral infections: a prospective, multicentre cohort study. *Clin. Microbiol. Infect.* **28**, 723–730 (2022).
- 50. Rocklöv, J. & Dubrow, R. Climate change: an enduring challenge for vector-borne disease prevention and control. *Nat. Immunol.* **21**, 479–483 (2020).
- 51. Matranga, C. B. *et al.* Unbiased Deep Sequencing of RNA Viruses from Clinical Samples. *J. Vis. Exp.* (2016) doi:10.3791/54117.
- 52. viral-ngs. viral-ngs v2.1.33.16. https://viralpipelines.readthedocs.io/en/v2.1.33.16/description.html (2023).
- 53. Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2. *Genome Biol.* **20**, 257 (2019).
- 54. Buchfink, B., Xie, C. & Huson, D. H. Fast and sensitive protein alignment using DIAMOND. *Nat. Methods* **12**, 59–60 (2015).
- 55. Trifinopoulos, J., Nguyen, L.-T., von Haeseler, A. & Minh, B. Q. W-IQ-TREE: a fast online phylogenetic tool for maximum likelihood analysis. *Nucleic Acids Res.* **44**, W232–5 (2016).
- 56. Rambaut. FigTree. (2018).
- 57. Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol. Biol. Evol.* **30**, 772–780 (2013).
- Capella-Gutiérrez, S., Silla-Martínez, J. M. & Gabaldón, T. trimAl: a tool for automated alignment trimming in large-scale phylogenetic analyses. *Bioinformatics* 25, 1972–1973 (2009).
- 59. Bolyen, E. *et al.* Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat. Biotechnol.* **37**, 852–857 (2019).
- 60. Rubinsteyn, A. & Feldman, S. fancyimpute: Version 0.0. 16. Version v0. 0.16. May (2016).
- 61. American Heart Association. Pediatric Advanced Life Support Provider Manual. (2016).
- 62. Chawla, N. V., Bowyer, K. W., Hall, L. O. & Kegelmeyer, W. P. SMOTE: Synthetic Minority Over-sampling Technique. *arXiv* [*cs.Al*] (2011).
- 63. Hancer, E., Xue, B. & Zhang, M. Differential evolution for filter feature selection based on information theory and feature ranking. *Knowledge-Based Systems* **140**, 103–119 (2018).
- 64. Guyon, I. & Elisseeff, A. An introduction to variable and feature selection. *J. Mach. Learn. Res.* **3**, 1157–1182 (2003).
- 65. Tibshirani, R. Regression Shrinkage and Selection via the Lasso. *J. R. Stat. Soc. Series B Stat. Methodol.* **58**, 267–288 (1996).
- 66. Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear Models via Coordinate Descent. *J. Stat. Softw.* **33**, 1–22 (2010).

#### Main figures:



Figure 1: Overview of burden of malarial and NMFI in Thiès, Senegal and NMFI pathogens identified in 2019 a. Patients suspected of malaria across 28 health facilities in the Thiès region (data provided by Programme National de lutte contre le Paludisme); gray shading indicates periods of sample collection for this study. b. Types of pathogens detected in febrile patients in dry and rainy seasons in 2019. Plasmodium detected by RDT or RNA-mNGS, bacterial infections detected by 16S amplicon sequencing, and viral infections detected by RNA-mNGS. c. Viral infections detected by RNA-mNGS d. Bacterial infections detected by 16S sequencing and e. Co-infections detected in febrile patients from 2019.



Figure 2: Characterization of qPCR-confirmed *Borrelia* and RDT-confirmed *Plasmodium* across both years **a**. *Borrelia*, *Plasmodium*, and non-*Borrelia* NMFI (Other febrile) incidence across dry and rainy seasons in 2018 and 2019. **b**. Age distribution of *Borrelia*, *Plasmodium*, and other febrile patients. **c**. Maximum likelihood phylogenetic tree (midpoint rooted) of IGS sequences from this study (red) in the context of available reference sequences for *B. crocidurae* (purple), *B. duttonii* (cyan), and *B. recurrentis* (green). For *B. crocidurae* isolates, location of collection indicated in label and host species indicated with node shape as available.



**Figure 3:** Clinical characteristics across both years of *Borrelia* (n = 39), *Plasmodium* (n = 75), and other febrile (n = 412) patients including **a.** symptoms reported by patients, **b.** exposures reported by patients, and **c.** vital signs. For 2019 only, **d.** blood cell counts in *Borrelia* (n = 17), *Plasmodium* (n = 41), other febrile (n = 146), and healthy (n = 104) **e.** Serological profile of a subset of patients with *Borrelia* (n = 9), *Plasmodium* (n = 11), viral infection (n = 10) compared to healthy patients (n = 10); cytokines/chemokines with at least one significant difference between groups shown [see Supplementary File 1 for results for all cytomkines/chemokines tested].

\*Mann-Whitney-Wilcoxon test two-sided, p-value annotation legend: ns: p <= 1.00e+00, \*: 1.00e-02 < p <= 5.00e-02, \*\*: 1.00e-03 < p <= 1.00e-03, \*\*\*: p <= 1.00e-04



**Figure 4:** Results of best performing weighted logisistic regression model to distinguish *Borrelia* infection from other NMFI using clinical data, including demographics, symptoms, exposures, and vital signs (trained on 2018-2019 data, tested on the same data with bootstrapping and cross-validation, n = 451). **a.** Model performance metrics and **b.** odds ratios for all features retained in the final model after feature selection.